glp-1 hims & Hers Stock Spikes. It's Taking on Ozempic and Wegovy With Cheap Obesity Shots Hims introduces GLP-1 weight loss

Lilly finished the third quarter with a combined $4.37 billion in sales for its two GLP-1 products based on the same active ingredient tirzepatidethe type 2 diabetes treatment Mounjaro and obesity drug Zepbound Mounjaro accounted for $3.112 billion of those Q3 sales, with Zepbound racking up the remaining $1.258 billion

Predictive analysis allows AI to aid in managing the disease and pharmacovigilance

Results include a reduction in fine lines, smoother skin, and a plump, rosy glow

The top 5 companies in the cardiovascular drugs industry account for approximately 70% of the market share, including Pfizer, Novartis, AstraZeneca, Bayer, and Johnson & Johnson